Article

Applied Clinical Trials

CRF Health’s TrialMax eCOA Solution Selected for Landmark Pain Outcomes Study

CRF Health announced that its TrialMax Touch and TrialMax Slate solutions have been selected by a Global Category Japanese Pharmaceutical company for a pain outcomes study. The Phase III trial will involve 800 screened and 320 randomized subjects across 40 sites in the US.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
Credit: Proxima Studio | stock.adobe.com. While BGM remains the regulatory gold standard, CGM is gaining ground in exploratory endpoints and safety monitoring
August 28th 2025

Beyond the Fingerstick: Navigating CGM and BGM Decisions in GLP-1 Clinical Trials

Karl McEvoy, PhD, and Aubrey Verna
ACT Brief Episode 6: Supreme Court Ruling, VK2735 Obesity Trial, and Padcev-Keytruda Survival Gains
August 28th 2025

ACT Brief Episode 6: Supreme Court Ruling, VK2735 Obesity Trial, and Padcev-Keytruda Survival Gains

Andy Studna, Senior Editor
Image Credit: Adobe Stock Images/Robin
August 28th 2025

Phase III NIMBLE Trial Demonstrates Cemdisiran Efficacy in Generalized Myasthenia Gravis

Andy Studna, Senior Editor
ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials
August 28th 2025

ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials

Andy Studna, Senior Editor
Credit: Dzmitry | stock.adobe.com. SMA can range from severe cases that develop during infancy to milder forms of the disease that manifest later in life.
August 28th 2025

Evrysdi Helps Presymptomatic Infants with Spinal Muscular Atrophy Sit, Stand, and Walk in Phase II Trial

Davy James
Phase I/II RAINFOL-01 Trial Results Lead to FDA Breakthrough Designation for Genmab’s Rina-S for Advanced Endometrial Cancer
August 28th 2025

Phase I/II RAINFOL-01 Trial Results Lead to FDA Breakthrough Designation for Genmab’s Rina-S for Advanced Endometrial Cancer

Don Tracy, Associate Editor
© 2025 MJH Life Sciences

All rights reserved.